Fig. 2: TBA-BT NCVs alter transcriptional activity.
From: Widespread perturbation of ETS factor binding sites in cancer
a Overview of the evaluation of NCVs by massively parallel reporter assays (MPRAs). b Fraction of NCVs from each test set within MPRA active regions that show expression allelic skew at different q-value thresholds in Jurkat, SK-MEL-28, and HT-29 cells. c Heatmap of validation rates in each cell line for NCVs present in 1, 2, 3, 4, and 5 or more patients. d Fraction of TFA-BT NCVs per recurrency (i.e., number of tumors with each NCV) across patients in PCAWG. Source data are provided as a Source Data file.
